CDV

What CDV does

CDV (Centro Diagnóstico Veterinario S.A.) is an Argentine privately-held veterinary biologics manufacturer founded in 1985, headquartered in Buenos Aires with three production facilities in Pilar Industrial Park. The company develops and produces a portfolio of more than 50 biological products — primarily vaccines (including brucellosis, foot-and-mouth disease, clostridial, and reproductive vaccines), diagnostics, and reproductive biotechnologies — that it sells under proprietary brands across livestock, aquaculture, companion-animal, and (newly) swine segments. Underlying technical capabilities include a proprietary compendium of SAS-licensed strains, double-emulsion adjuvants, and per-dose QR-coded serialization; the company holds GMP certification (granted 2015, recertified) and is actively pursuing PIC/S certification, which would position CDV as the first such facility in Latin America.

The business is B2B, distributing through veterinary professionals, livestock-producer channels, and government-mandated vaccination programs (notably Argentina's SENASA brucellosis LRO223 plan and foot-and-mouth campaigns). Revenue mechanics combine (i) high-volume, regulated livestock vaccine tenders — both domestic and export — with (ii) higher-margin specialty biologics and reproductive biotechnologies for commercial herds and aquaculture. The company exports to more than 20 countries, has filed 200+ new international product registrations in the past year, and targets roughly 35% market share in brucellosis vaccines with the majority of that volume earmarked for international markets.

Operating model is currently in a heavy capex and expansion phase: a ~$80 million Plant 3 came online in 2025, lifting projected total capacity to ~280 million doses and opening pig and companion-animal product lines; a dedicated $4 million brucellosis plant was commissioned in mid-2024; a US-based R&D subsidiary was established in 2024 to develop mRNA and recombinant-protein platforms; and an 80% renewable-electricity partnership with Genneia (2024) addresses both ESG profile and Argentine power-cost exposure. CDV is family/owner-controlled and has been independently recognized with Best Latin American Veterinary Company (2019, 2023) and Best Animal Health Company Worldwide (2024) awards; no outside investor or public-market signal is present in the available data.

Name

CDV

Legal name

Centro Diagnóstico Veterinario S.A.

Website

https://cdv.com.ar

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

101–250 employees

Short description

CDV is an Argentine veterinary biologics manufacturer founded in 1985 that produces 50+ vaccines and diagnostics for livestock, aquaculture, swine, and companion animals, operating three plants in Buenos Aires and exporting to 20+ countries.

Ownership category

akta.pro rank

Product category

Veterinary Biologics / Animal Health Vaccines

NAICS

Veterinary Services (541940), Medical Laboratories (621511)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology) (HLAMADAC), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary vaccines
• Animal biologics
• Diagnostic reagents
• Foot-and-mouth vaccines
• Aquaculture vaccines

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Vaccine Sales: CDV generates revenue primarily through the sale of biological vaccines for animal health including viral vaccines, bacterial vaccines, foot-and-mouth vaccines, and diagnostic reagents. The company sells over 50 biological products across multiple product lines.
2. Diagnostic Services: Revenue from laboratory diagnostic services providing analysis for veterinary species including parasitology, bacteriology, virology, serology, and molecular diagnosis (PCR). Services include interpretation of results for veterinarians.
3. International Trade: CDV exports products to more than 20 countries with 70% of brucelosis vaccine production destined for international markets, primarily Latin America, Asia, and Middle East.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

CDV researches, develops, and produces at industrial scale veterinary biological products — viral and bacterial vaccines (including foot-and-mouth, brucelosis, rabia, clostridial, reproductive, respiratory, neonatal diarrhea, and keratoconjunctivitis vaccines), aquaculture vaccines under the AGROVAC brand, and diagnostic reagents. The company also operates an in-house veterinary diagnostic laboratory providing parasitology, bacteriology, virology, serology, and molecular PCR analysis for livestock, aquaculture, and companion animal species.

Differentiator

Problem solved

Functional benefit

Brands

• CDVac: CDV's primary brand for veterinary biological vaccines (e.g., CDVac Feedlot Plus, CDVac Reproductiva Plus, CDVac Rabia, CDVac Brucelosis).
• AGROVAC

Products and services

• CDVac Livestock Vaccine Line (CDVac Reproductiva, Respiratoria, Clostridiales, Queratoconjuntivitis, Diarrea Neonatal, Carbunclo/Anthrax, Rabia) Complete CDVac branded line of viral and bacterial vaccines for prevention of reproductive, respiratory, clostridial, ocular, neonatal enteric, and zoonotic diseases (Brucelosis, Rabia, Carbuncle, Leptospirosis) in bovine and ovine herds. Sold to commercial livestock producers and veterinarians.
• Foot-and-Mouth (Aftosa) Vaccines Foot-and-mouth disease vaccines produced exclusively at Plant 2 (BSL-4 OIE certified, USD 40+ million investment) with annual capacity of more than 60 million doses. Used in national and regional FMD control programs.
• AGROVAC Aquaculture Vaccines AGROVAC branded vaccines (AGROVAC 2, AGROVAC 3, AGROVAC 4, AGROVAC ISA, AGROVAC IPN and others) for prevention of Streptococcus agalactiae, Piscirickettsiosis, IPN, ISA, and Aeromonas salmonicida in tilapia, Atlantic salmon, Coho salmon, Chinook salmon, and rainbow trout. Sold to commercial fish farms.
• Veterinary Diagnostic Laboratory Services In-house diagnostic laboratory providing parasitology, bacteriology, virology, serology, and molecular PCR analysis for livestock, aquaculture, and companion animal species, with specialized expertise in bovine reproductive disease diagnosis (Trichomoniasis, Campylobacteriosis) and official brucelosis/leucosis testing under SENASA. Interpretation of results is provided to veterinarians.
• Diagnostic Reagents Diagnostic reagent product line including 3 products for veterinary laboratory use, supporting disease identification and monitoring across multiple species. Sold to veterinary laboratories and practitioners.
• Brucelosis Vaccine Line (Cepa 19 and RB51) Brucelosis vaccines (Cepa 19 and RB51 strains) produced in a dedicated Plant 1 expansion (USD 4 million investment, 10 million dose capacity, production began July 2024). Used in national brucelosis eradication programs and export to 20+ countries, with 70% of production destined for international markets.

Quantifiable outcome

• Prevention of major zoonotic diseases including Brucelosis, Rabia, and Carbuncle in livestock
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• GenneiacoreStrategic or Co-development Partner · 21 October 2024Strategic partnership for renewable energy supply through the private Renewable Energy Market (MATER) system. 7-year contract with option to renew. 80% of CDV's three vaccine production plants powered by wind and solar energy from Genneia's parks. This makes CDV the first Argentine veterinary laboratory to use 80% renewable energy, reducing CO2 emissions and achieving carbon offset.
• SENASA (Servicio Nacional de Sanidad Animal)coreStrategic or Co-development PartnerCDV is a member of the SENASA Official Laboratory Network (Red de Laboratorios de SENASA) with identification LRO223. Operates as an official diagnostic laboratory for brucelosis and enzootic bovine leucosis testing. Complies with all SENASA requirements for production and control of vaccines.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• HIPRA: Spanish veterinary biologics specialist focused on livestock and aquaculture vaccines, with strong R&D pipeline and emerging international presence. Directly comparable to CDV's inactivated/live vaccine manufacturing model and serves overlapping markets in Latin America, Asia, and Europe.
• Biogénesis Bagó: Argentine veterinary biologics manufacturer and one of CDV's closest direct competitors, particularly in foot-and-mouth vaccines (FMD) and bovine biologics across Latin America. Operates similar product categories and serves overlapping export markets, making it the most comparable peer to CDV's core livestock vaccine franchise.

Emerging players

• Benchmark Holdings (Aquaculture Health): UK-listed aquaculture health specialist offering vaccines and diagnostics for salmon, tilapia, and other farmed fish. Comparable to CDV's AGROVAC aquaculture franchise, particularly in salmon vaccines (IPN, ISA, Piscirickettsiosis), though Benchmark is more specialized in aquaculture.
• Indian Immunologicals Limited: Indian veterinary biologics manufacturer (owned by the National Dairy Development Board) producing livestock and human vaccines. Comparable to CDV as an emerging-market vaccine manufacturer scaling international exports, though focused primarily on bovine/ovine species in South Asia and Africa.

Broad incumbents

• MSD Animal Health (Merck Animal Health): Global animal health incumbent with broad vaccine portfolio spanning livestock, companion animal, and aquaculture species. Competes with CDV in aquaculture vaccines (notably salmon/piscirickettsiosis), livestock vaccines, and is increasingly active in Latin American markets.
• Zoetis: The world's largest pure-play animal health company, offering vaccines, diagnostics, and pharmaceuticals across livestock and companion animals. Competes with CDV in FMD, brucelosis, and reproductive/respiratory vaccines globally, but at materially larger scale and across the full species spectrum.
• Ceva Santé Animale: Major independent global animal health company with a broad vaccine portfolio across poultry, swine, ruminants, and companion animals. Competes with CDV in poultry/swine vaccines and has a strong presence in emerging markets overlapping with CDV's Latin American and Asian footprint.
• Virbac: Independent global animal health player with focus on vaccines, parasiticides, and diagnostics for both livestock and companion animals. Comparable to CDV as a mid-sized vaccine manufacturer with international reach, though Virbac is more diversified across species and product categories.
• Boehringer Ingelheim Animal Health: Top-three global animal health player with strong livestock vaccine franchise and expanding companion animal portfolio. Competes with CDV in reproductive, respiratory, and clostridial vaccines for bovine/ovine species across Latin America and export markets.

Regional players

• Vencofarma Laboratórios: Brazilian veterinary products manufacturer serving the Latin American livestock market. Comparable to CDV as a regional South American animal health player with overlapping customers in beef and dairy cattle, though with a more diversified product portfolio including parasiticides and pharmaceuticals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LabCDV
• YouTubeyoutube.com/channel/UCg3KQNGs_fR7BcRZszEN47A
• Facebookfacebook.com/LabCDV
• LinkedInlinkedin.com/company/labcdv
• Instagraminstagram.com/labcdv

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CDV